Why Disease Turns Soft Tissue Into Bone?
Scientists have created a new mouse model that may help researchers explain how a rare disease causes otherwise supple soft tissue and joints to turn into bone.
Fibrodysplasia ossificans progressiva (FOP) is a rare congenital disease that affects the connective tissue, causing muscles, ligaments, and other soft tissues to turn to bone. The process of ossification often occurs following traumatic injury to the soft tissue, and can progress over time to cause nearly all joints of the body to become permanently frozen in place. Affected individuals develop problems speaking, breathing, and eating. There is no treatment, and many people who have FOP die in their twenties or thirties.
Using genetically modified mice, Paul Yu and his colleagues have developed a model that mirrors many aspects of the bone-forming disease. The scientists have shown that treating these mice with a drug that blocks the overactive receptor that causes FOP can reduce abnormal bone growth and preserve joint function.
In 2008, Yu received an Early Career Physician-Scientist Award from the Howard Hughes Medical Institute (HHMI) that provides promising physician-scientists with the financial support needed to develop their research programs at the beginning of their academic careers. The award is part of a long-time push by HHMI to increase the number researchers who translate basic science discoveries into improved treatment for patients.
Yu, who is at Massachusetts General Hospital and Harvard Medical School in Boston, said the mice harbor a mutation to very similar to those found in humans with the FOP. "The mice appear to develop the lesions only after there is injury or inflammation, which reminiscent of the fact that the human disease frequently flares up in the setting of trauma or viral illness." Although he is encouraged by this advance, Yu remains cautious about his team's results. The mouse model has some characteristics that are different from the human disease, including having a mutation distinct from that of affected humans, he says, and researchers are still far from testing the drug on humans who have FOP.
Several years ago, scientists linked FOP to overactivity of the bone morphogenetic protein (BMP) signaling pathway. BMP signals help control tissue repair and regulates the differentiation of cells into specialized tissue. BMP signals normally facilitate the development of the skeleton, as well as the specialized structures of organs. Recent studies from Frederick Kaplan and Eileen Shore at the University of Pennsylvania showed that the molecular defect that causes FOP most frequently results from an inherited mutation in the BMP receptor, ALK2. The mutation results in uncontrolled BMP signaling.
At the outset of his medical career, Yu had no idea he would one day study this mysterious disease. As a medical student, he participated in the HHMI Medical Fellows Program, which permitted him to spend a year in the lab of Jeffrey Platt at Duke University Medical School. (Platt is now at the University of Michigan.) There, he studied antibodies that cause rejection in an experimental organ transplantation model. After completing his M.D. and Ph.D. studies, as well as internal medicine and cardiology training, Yu pursued postdoctoral research at Massachusetts General Hospital with his mentor Kenneth Bloch, studying the function of BMPs in the heart and circulatory system. "BMP signaling affects the development of the blood vessels and the heart. In the course of studying that I realized that there weren't very many pharmacologic tools for manipulating BMP signaling," Yu says. At Harvard, Yu worked with a colleague Charles Hong (now at Vanderbilt University), who identified a chemical that inhibited the function of BMP signals in developing zebrafish.